BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lewitt PA, Lipsman N, Kordower JH. Focused ultrasound opening of the blood–brain barrier for treatment of Parkinson's disease. Mov Disord 2019;34:1274-8. [DOI: 10.1002/mds.27722] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Foffani G, Trigo‐damas I, Pineda‐pardo JA, Blesa J, Rodríguez‐rojas R, Martínez‐fernández R, Obeso JA. Focused ultrasound in Parkinson's disease: A twofold path toward disease modification. Mov Disord 2019;34:1262-73. [DOI: 10.1002/mds.27805] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
2 Colombo D, Pnevmatikou P, Melloni E, Keywood C. Therapeutic innovation in Parkinson's disease: a 2020 update on disease-modifying approaches. Expert Rev Neurother 2020;20:1047-64. [PMID: 32758042 DOI: 10.1080/14737175.2020.1800454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Prieto Huarcaya S, Drobny A, Marques ARA, Di Spiezio A, Dobert JP, Balta D, Werner C, Rizo T, Gallwitz L, Bub S, Stojkovska I, Belur NR, Fogh J, Mazzulli JR, Xiang W, Fulzele A, Dejung M, Sauer M, Winner B, Rose-John S, Arnold P, Saftig P, Zunke F. Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models. Autophagy 2022. [PMID: 35287553 DOI: 10.1080/15548627.2022.2045534] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Fischell JM, Fishman PS. A Multifaceted Approach to Optimizing AAV Delivery to the Brain for the Treatment of Neurodegenerative Diseases. Front Neurosci 2021;15:747726. [PMID: 34630029 DOI: 10.3389/fnins.2021.747726] [Reference Citation Analysis]
5 Buttery PC, Barker RA. Gene and Cell-Based Therapies for Parkinson's Disease: Where Are We? Neurotherapeutics 2020;17:1539-62. [PMID: 33128174 DOI: 10.1007/s13311-020-00940-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
6 Naki T, Aderibigbe BA. Efficacy of Polymer-Based Nanomedicine for the Treatment of Brain Cancer. Pharmaceutics 2022;14:1048. [DOI: 10.3390/pharmaceutics14051048] [Reference Citation Analysis]
7 Grosso Jasutkar H, Oh SE, Mouradian MM. Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease. Pharmacol Rev 2022;74:207-37. [PMID: 35017177 DOI: 10.1124/pharmrev.120.000133] [Reference Citation Analysis]
8 Park B, Yoon S, Choi Y, Jang J, Park S, Choi J. Stability of Engineered Micro or Nanobubbles for Biomedical Applications. Pharmaceutics 2020;12:E1089. [PMID: 33202709 DOI: 10.3390/pharmaceutics12111089] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Gasca-Salas C, Fernández-Rodríguez B, Pineda-Pardo JA, Rodríguez-Rojas R, Obeso I, Hernández-Fernández F, Del Álamo M, Mata D, Guida P, Ordás-Bandera C, Montero-Roblas JI, Martínez-Fernández R, Foffani G, Rachmilevitch I, Obeso JA. Blood-brain barrier opening with focused ultrasound in Parkinson's disease dementia. Nat Commun 2021;12:779. [PMID: 33536430 DOI: 10.1038/s41467-021-21022-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
10 Roshani M, Kiaie N, Aghdam RM. Biomaterials and stem cells as drug/gene-delivery vehicles for Parkinson's treatment: an update. Regen Med 2021;16:1057-72. [PMID: 34865515 DOI: 10.2217/rme-2021-0050] [Reference Citation Analysis]
11 Wang JB, Di Ianni T, Vyas DB, Huang Z, Park S, Hosseini-Nassab N, Aryal M, Airan RD. Focused Ultrasound for Noninvasive, Focal Pharmacologic Neurointervention. Front Neurosci 2020;14:675. [PMID: 32760238 DOI: 10.3389/fnins.2020.00675] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]